MONTREAL, August 30, 2022 – CQDM is very pleased to announce the nomination of John Delaney and Jennifer Hamilton as members of the Scientific Advisory Board (SAB). The SAB is a key committee for CQDM as it provides strategic guidance regarding biopharmaceutical innovation and oversees the selection of projects funded by CQDM.
John Delaney is an active retiree sitting on multiple Boards. He led Amgen’s Biologic Discovery division, responsible for identifying large molecule therapeutic candidates, including the discovery of fully human antibody therapeutics, in collaboration with all Amgen Therapeutic Areas, using the company’s proprietary platform technology. He joined Amgen in 1992 and led research teams in numerous Amgen locations. John holds a Bachelor of Science in Zoology from the University of Montana and earned his Ph.D. in the Department of Microbiology at the University of Arizona. He completed his postdoctoral training at the University of Utah’s Department of Cellular, Viral, and Molecular Biology.
Jennifer Hamilton is a Life Sciences executive with experience working with big Pharma and venture capital funds. Most recently, she spent 11 years at Johnson & Johnson Innovation, as Country Lead, and was responsible for Search & Evaluation and transactions in Canada. In that role, she scoured Canadian universities, incubators, and companies for technologies of interest to Johnson & Johnson, and coordinated and monitored research collaborations and license agreements. Prior to that, she spent 10 years as Venture Partner at UK-based Nomura Phase4 Ventures, and 5 years at Rothschild Asset Management, both international life sciences funds. She is currently an adviser and BOD member to biotechnology companies and venture funds. Jennifer has a Ph.D. in Experimental Pathology / Lipid Metabolism from the University of British Columbia.
“We are delighted to welcome John and Jennifer to our SAB. Their unique pharmaceutical expertise will bring outstanding feedback to CQDM funded researchers and scientists of our ecosystem,” said Diane Gosselin, President and CEO of CQDM.
“I am enthusiastic to welcome these new members to our Scientific Advisory Board, as their great expertise will strengthen the expertise of our committee,” said Brian Underdown, chairman of CQDM’s SAB.
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Quebec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned.